AMGEN Inc
NASDAQ: AMGN
$263.38
+$2.19 (+0.8%)
Closing Price on December 20, 2024
AMGN Articles
The November 13 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Published:
Thursday's top analyst upgrades and downgrades included Amgen, Boeing, eBay, Etsy, Fastly, Fiverr, Ford, General Electric, Gilead Sciences, Pinterest and Six Flags.
Published:
Amgen and Gilead released their most recent financial results after the closing bell on Wednesday.
Published:
The October 15 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Published:
Tuesday's top analyst upgrades and downgrades included Advanced Micro Devices, Amazon.com, Amgen, Biogen, Hasbro, Kinder Morgan, SAP, Spotify and Twitter.
Published:
Monday's top analyst upgrades and downgrades included Advanced Micro Devices, Amgen, Asana, Baidu, First Solar, Mattel, Mirati Therapeutics, Palantir Technologies, Pinterest, SAP and Zscaler.
Published:
Roughly a third of the Dow Jones industrial average components are scheduled to report their latest quarterly reports this week.
Published:
Earnings season is upon us and investors are pining for information about which stocks and sectors will do well. After all, many investors missed the bulk of the recovery from March’s panic selling...
Published:
The September 30 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Published:
24/7 Wall St. has been reviewing many sectors for leadership heading into earnings. One area that can offer some defensive strategies is biotech and pharmaceuticals.
Published:
Friday's top analyst upgrades and downgrades included AMD, Amazon.com, Amgen, Chevron, Exxon Mobile, General Electric, IBM, Lowe's Companies, Marvell Technology, Rocket Companies, 3D Systems and ...
Published:
Last Updated:
The September 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Published:
Credit Suisse has set an Outperform rating and $290 price target on Amgen shares. That target implies more than 20% upside to the stock's recent trading price.
Published:
As an approved COVID-19 vaccine nears completion in terms of clinical trials, what can we expect? In the past couple of weeks, firms working toward this goal have taken steps forward and back, which...
Published:
Here is how the Dow Jones industrial average can still continue to rise and hit the 30,000 mark by year's end.
Published: